Robert Younger, MD
Allergy & Immunology · Ooltewah, TNNPI 1629017819
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,875 of the $36,267 with a category attached, or 82.4%. AstraZeneca accounts for 76.3% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $17,244 and has fallen 99.8% since, to $31 in 2025.
Across 326 payments — averaging $111.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$28K
- Genentech USA, Inc.$4K
- Regeneron Healthcare Solutions, Inc.$726
- GSK$588
- Takeda Pharmaceuticals U.S.A., Inc.$531
- Sanofi$373
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$29,87582%
- Travel & lodging$5682%
- Food & beverage$5,82416%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 100 | $27,674 |
| Genentech USA, Inc. | 13 | $4,494 |
| Regeneron Healthcare Solutions, Inc. | 30 | $726 |
| GSK | 44 | $588 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $531 |
| Sanofi | 16 | $373 |
| CSL Behring | 12 | $249 |
| Pfizer | 14 | $218 |
| Novartis | 13 | $198 |
| Grifols USA, LLC | 10 | $167 |
| Optinose US, Inc. | 8 | $148 |
| Kaleo, Inc. | 8 | $128 |
| Octapharma USA, Inc. | 2 | $127 |
| Amgen(2 entities) | 5 | $104 |
| Boehringer Ingelheim | 5 | $77 |
| Shire North American Group Inc | 3 | $66 |
| Mylan Specialty L.p. | 3 | $65 |
| Pharming Healthcare, Inc. | 2 | $50 |
| Biocryst US Sales Co., LLC | 2 | $42 |
| Hikma Pharmaceuticals USA | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Alcon | 1 | $31 |
| Dermavant Sciences, Inc. | 1 | $25 |
| Alk-abello, Inc | 1 | $24 |
| Phadia US Inc. | 1 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Incyte Corporation | 1 | $18 |
| Merck | 1 | $18 |
| ADMA Biomanufacturing LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,267 in reported general payments places this provider in the 80th percentile of 79 allergy & immunology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 133 | $160,876 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $135,339 |
| TezspireTezepelumab-Ekko | 26 | $102,091 |
| XolairOmalizumab | 45 | $99,238 |
| Dupixent PenDupilumab | 20 | $74,429 |
| Breo ElliptaFluticasone/Vilanterol | 92 | $62,165 |
| Dupixent SyringeDupilumab | 12 | $43,602 |
| Arnuity ElliptaFluticasone Furoate | 48 | $19,867 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $17,145 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $10,510 |
| Epinephrine | 29 | $5,401 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $4,728 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $3,872 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 153 | $3,627 |
| BreynaBudesonide/Formoterol Fumarate | 16 | $3,626 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $588 | $242,908273 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $531 | $135,33912 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $27,674 | $129,74667 claims |
| Hikma Pharmaceuticals USAEpinephrine | $34 | $5,40129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 79 allergy & immunology providers in Tennessee.
Other allergy & immunology in Ooltewah
- Nicholas KolinskyKnoxville$472K
- Tidence PrinceMaryville$269K
- Tammy Heinly McCulleyGermantown$165K
- Phillip LiebermanMemphis$131K
- John FahrenholzNashville$124K
- Marc CromieChattanooga$106K
- Reena PatelMemphis$101K
- Jay LiebermanMemphis$81K
- Katherine CahillNashville$73K
- Todd LevinChattanooga$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.